Pharvaris NV
PHVSHealthcare|Biotechnology|Netherlands
$35.02
-0.86 (-2.39%)
Tangible Book
$4.18
Earnings Power
$4.31
Upcoming Data Readouts (3)
Aug 2026
Est. completion
P3Hereditary Angioedema (HAE)
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754n=81
Jun 2027
Est. completion
P3Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805n=32
Dec 2028
Est. completion
P3Hereditary Angioedema (HAE)
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881n=170